LeMaitre Vascular (NASDAQ:LMAT) Issues Quarterly Earnings Results

LeMaitre Vascular (NASDAQ:LMAT) announced its quarterly earnings data on Thursday. The medical instruments supplier reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.05, Briefing.com reports. The firm had revenue of $53.48 million during the quarter, compared to analysts’ expectations of $51.50 million. LeMaitre Vascular had a return on equity of 10.57% and a net margin of 15.56%. The company’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.27 EPS. LeMaitre Vascular updated its Q2 guidance to $0.45-0.50 EPS and its FY24 guidance to $1.73-1.84 EPS.

LeMaitre Vascular Trading Up 11.2 %

Shares of LMAT stock traded up $7.45 on Friday, reaching $74.22. The company had a trading volume of 329,984 shares, compared to its average volume of 116,703. The company has a 50-day moving average of $65.93 and a 200-day moving average of $58.71. LeMaitre Vascular has a 12 month low of $44.27 and a 12 month high of $74.64. The stock has a market cap of $1.67 billion, a PE ratio of 55.39, a PEG ratio of 2.88 and a beta of 0.88.

LeMaitre Vascular Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Thursday, March 14th were paid a $0.16 dividend. The ex-dividend date was Wednesday, March 13th. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.14. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.86%. LeMaitre Vascular’s dividend payout ratio is 47.76%.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Stifel Nicolaus raised LeMaitre Vascular from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $59.00 to $75.00 in a report on Friday, April 26th. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. Barrington Research boosted their price objective on LeMaitre Vascular from $69.00 to $79.00 and gave the stock an “outperform” rating in a report on Friday. JMP Securities upped their price target on LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a research note on Friday. Finally, KeyCorp initiated coverage on LeMaitre Vascular in a research note on Tuesday, February 6th. They issued a “sector weight” rating for the company. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, LeMaitre Vascular has a consensus rating of “Moderate Buy” and a consensus target price of $73.83.

Insider Buying and Selling

In related news, Director Lawrence J. Jasinski sold 5,110 shares of the stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total transaction of $344,925.00. Following the completion of the sale, the director now directly owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director Lawrence J. Jasinski sold 5,110 shares of the stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total transaction of $344,925.00. Following the completion of the sale, the director now directly owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director John A. Roush sold 7,500 shares of the stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $69.00, for a total value of $517,500.00. Following the sale, the director now directly owns 2,278 shares of the company’s stock, valued at $157,182. The disclosure for this sale can be found here. In the last three months, insiders sold 114,036 shares of company stock valued at $7,873,749. 10.79% of the stock is owned by corporate insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.